However, patients at the advanced stage (BCLC stage C) can benefit from systemic therapies, employing tyrosine kinase inhibitor family molecules, such as sorafenib, regorafenib, lenvatinib, cabozantinib targeting pro-angiogenic, and oncogenic factors, VEGFR1–3, FGFR 1–4, PDGFR alpha, RET, KIT, with the inhibition of multiple oncogenic and angiogenic pathways implicated in tumor progression and metastasis, with a significant benefit of survival. Here, KIT is linked to neoplasm.